STRAP and NME1 Mediate the Neurite Growth-Promoting Effects of the Neurotrophic Factor GDF5

HIGHLIGHTS

Mechanism of action of dopaminergic neurotrophic factor GDF5 is not fully understood

Increased expression of STRAP and NME1 is needed for neurite growth promotion by GDF5

NME1 increases neurite growth in SH-SY5Y cells and midbrain dopaminergic neurons

STRAP and NME1 co-expression patterns are altered in Parkinson’s disease midbrain

Anantha et al., iScience 23, 101457
September 25, 2020 © 2020
The Author(s).
https://doi.org/10.1016/j.isci.2020.101457
STRAP and NME1 Mediate the Neurite Growth-Promoting Effects of the Neurotrophic Factor GDF5

Jayanth Anantha,1 Susan R. Goulding,1,2 Sean L. Wyatt,3 Ruth M. Concannon,1 Louise M. Collins,1,4 Aideen M. Sullivan,1,5,6,* and Gerard W. O’Keeffe1,5,6,7,*

SUMMARY

Loss of midbrain dopaminergic (mDA) neurons and their axons is central to Parkinson’s disease (PD). Growth differentiation factor (GDF)5 is a potential neurotrophic factor for PD therapy. However, the molecular mediators of its neurotrophic action are unknown. Our proteomics analysis shows that GDF5 increases the expression of serine threonine receptor-associated protein kinase (STRAP) and nucleoside diphosphate kinase (NME)1 in the SH-SY5Y neuronal cell line. GDF5 overexpression increased NME1 expression in adult rat brain in vivo. NME and STRAP mRNAs are expressed in developing and adult rodent midbrain. Expression of both STRAP and NME1 is necessary and sufficient for the promotion of neurite growth in SH-SY5Y cells by GDF5. NME1 treatment increased neurite growth in both SH-SY5Y cells and cultured mDA neurons. Expression patterns of NME and STRAP are altered in PD midbrain. NME1 and STRAP are thus key mediators of GDF5’s neurotrophic effects, rationalizing their future study as therapeutic targets for PD.

INTRODUCTION

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting 1% of the population older than 60 years (Lees et al., 2009; Tysnes and Storstein, 2017). The neuropathological hallmarks of PD include the progressive degeneration of midbrain dopaminergic (mDA) neurons and their axons that project to the striatum via the nigrostriatal pathway (Burke and O’Malley, 2013; Caminiti et al., 2017; O’Keeffe and Sullivan, 2018). The application of neurotrophic factors to halt and potentially reverse the degeneration of the nigrostriatal pathway holds significant promise as a disease-modifying therapy for PD (Kelly et al., 2015; Sullivan and O’Keeffe, 2016). However, despite promising results in open-label clinical trials (Gill et al., 2003; Slevin et al., 2007; Marks et al., 2008), subsequent randomized double-blind trials of the dopaminergic neurotrophic factors, glial cell line-derived neurotrophic factor (GDNF) and neurturin, failed to meet their primary endpoints (Lang et al., 2006; Marks et al., 2010; Warren Olanow et al., 2015; Whone et al., 2019). This has been suggested to be due to the downregulation of Ret, the common co-receptor for GDNF and neurturin, by alpha-synuclein (Decressac et al., 2012), a protein that is present in aggregates, called Lewy bodies, in the PD brain. Additional studies have shown that there is an absolute requirement for Ret for the neurotrophic effect of GDNF on mDA neurons in vivo (Drinkut et al., 2016). It is therefore important to characterize the effects of other factors that have neurotrophic effects on mDA neurons, and to decipher the molecular mechanisms that underlie their beneficial effects on this neuronal population.

One such neurotrophic factor is GDF5, a member of the transforming growth factor (TGF)-β superfamily, which was originally identified through its key role in limb development in mice and humans (Kriegstein and Unsicker, 1995; Storm et al., 1994; Storm and Kingsley, 1996). As a member of the TGF-β superfamily, GDF5 is a distant relative of GDNF and has been demonstrated to have similar neuroprotective effects to those of GDNF on mDA neurons in vitro (Jaumotte and Zigmond, 2014) and in vivo (Sullivan et al., 1998). The neurotrophic and neuroprotective effects of GDF5 have been extensively studied in vivo animal models of PD (Sullivan et al., 1997; 1998; Costello et al., 2012; Hurley et al., 2004). In addition, GDF5 has been shown to promote neurite growth in cultured rat dopaminergic (O’Keeffe et al., 2004a, 2004b; Hegarty et al., 2014) and sympathetic neurons (O’Keeffe et al., 2016), and in the SH-SY5Y human...
neuroblastoma cell line (Hegarty et al., 2013), which are widely used in vitro models of PD. GDF5 has also been reported to enhance neurite complexity, in a hairy enhancer of split (HES)5-dependent manner, in cultured rat hippocampal pyramidal neurons (Osono et al., 2013).

The neurotrophic effects of GDF5 are exerted through the canonical bone morphogenetic protein (BMP) pathway, which involves signaling through a complex of its two receptors, BMPR1B and BMPR2, resulting in phosphorylation and activation of R-Smad transcription factors, Smad1, Smad5, and Smad9 (Hegarty et al., 2013; Liu et al., 2016). These Smads subsequently form a transcription factor complex with Smad4, which translocates to the nucleus and transcribes target genes (Makkar et al., 2009). This pathway has been shown to mediate the effects of GDF5 in SH-SY5Y cells (Hegarty et al., 2013), cultured rat mDA neurons (Hegarty et al., 2014), and cultured rat sympathetic neurons (O’Keeffe et al., 2016). Silencing of Zinc finger E-box-binding homeobox (ZEB) 2, an inhibitor of the BMP-Smad pathway, resulted in enhanced striatal dopaminergic innervation in cultured rat mDA neurons; furthermore, Zeb2-deficient mice display dopaminergic hyperinnervation of the striatum (Hegarty et al., 2017). This role for the BMP-Smad pathway in striatal dopaminergic innervation is of interest because nigrostriatal axonal degeneration is a key early pathological process in PD (for reviews see Burke and O’Malley, 2013; O’Keeffe and Sullivan, 2018). The fact that GDF5 can exert neurotrophic actions through this Ret-independent pathway is important, given the failure of the Ret-dependent factors, GDNF and neurturin, in clinical trials (Lang et al., 2006; Marks et al., 2010; Warren Olanow et al., 2015; Paul and Sullivan, 2018; Whone et al., 2019). The Ret receptor is thought to be downregulated by alpha-synuclein, which accumulates in the PD brain (Decressac et al., 2012); thus there is a drive to identify and test alternative dopaminergic neurotrophic factors that are not dependent on Ret for signaling. Ret-independent factors that act via receptors and signaling molecules that are not affected by the neuropathology of PD have potential as therapeutic agents.

GDF5 and its receptors are expressed in a temporally and spatially regulated manner in the pre- and postnatal developing embryonic mouse brain, suggesting that GDF5 plays a role in brain development (O’Keeffe et al., 2004b; Hegarty et al., 2014). The expression profiles of GDF5 and GDNF and their receptors differ in hydroxydopamine (6-OHDA) lesion in in vivo models of PD. In both striatal and medial forebrain bundle (MFB) lesion models, striatal levels of GDF5 mRNA were increased at 10 days post-lesion, whereas GDNF mRNA levels in the nigrostriatal system were decreased after 10 and 28 days (Gavin et al., 2014). Expression of GDF5's receptors, BMPR1B and BMPR2, was unperturbed in both striatal and MFB-lesioned rats, whereas mRNA levels of the GDNF receptors, Ret and GFRα1, were significantly decreased (Gavin et al., 2014).

Although the protective effects of GDF5 on dopaminergic neurons have been validated in vitro and in vivo, and the receptors and some of the signaling pathways are known, there is a need for further information regarding the molecular pathways that mediate the effects of GDF5 on mDA neurons, to facilitate the development of targeted therapeutic approaches for PD. To address this, we used the SH-SYSY cell line to study the effects of GDF5 on the proteome. We initially used SH-SYSY cells rather than primary dopaminergic neuronal cultures for the proteomics screen, to have a more homogeneous population of cells for analysis. SH-SYSY cells are widely used in cell biological studies as an in vitro model of relevance to PD (Xicoy et al., 2017). Furthermore, GDF5 has similar neurotrophic effects on, and acts via the same pathway in, SH-SYSY cells as it does in cultured rat mDA neurons (Hegarty et al., 2013, 2014), meaning that this cell line can be used to screen for molecular mechanisms of relevance to mDA neurons.

RESULTS
GDF5 Activates Smad Signaling and Induces a Transcriptional Response in SH-SYSY Cells

We first confirmed that GDF5 treatment of SH-SYSY cells activated the canonical BMP-Smad signaling pathway. To do this, SH-SYSY cells were plated for 24 h before they were treated with 100 ng/mL recombinant human GDF5 for 30, 60, or 120 min. Western blotting revealed a significant increase in the levels of phospho (p)-Smad1/5/9, which peaked at 30 min after treatment (Figures 1A and 1B). We next validated these findings by treating SH-SYSY cells with GDF5 for 30 min and immunocytochemically staining them for p-Smad1/5/9 and counterstaining with GAPDH and DAPI (Figure 1C). Quantification of the relative nuclear fluorescence intensity revealed a significant increase in the levels of p-Smad1/5/9 after GDF5 treatment (Figure 1D). Finally, to confirm that GDF5-induced increases in p-Smad1/5/9 translated to a transcriptional response, we examined the expression of transcripts for the Hes5 and Zeb2, which are known downstream targets of the BMP-Smad pathway. Real-time PCR confirmed that a 240-min treatment with
100 ng/mL GDF5 led to a significant increase in the expression of Hes5 and Zeb2 mRNA (Figures 1E and 1F). Collectively, these data show that GDF5 activates canonical BMP-Smad signaling in SH-SY5Y cells, making them a suitable model for a proteomics screen to identify novel mediators of the effects of GDF5.

**GDF5-Induced Changes in the Proteome in SH-SY5Y Cells and Gene Co-expression Analysis Using Data from the Human Substantia Nigra (SN) Identifies Correlated Patterns of STRAP and NME1 Expression**

To identify novel regulators of the neurotrophic effects of GDF5, we carried out an untargeted proteomics analysis of human SH-SY5Y cells treated with GDF5 (Figure 2A). SH-SY5Y cells were treated with 100 ng/mL GDF5 for 240 min. Total proteins were then extracted from cell lysates and analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The resulting peptides were identified using MaxQuant (version 1.6.0.16). A false discovery rate (FDR) of 1% was used to identify unique peptides mapping to a protein. The resulting label-free quantification (LFQ) values were used to calculate the fold change and p values. The \(-\log_{10}p\) value and the \(\log_{2}\)Fold change were calculated and plotted in a volcano plot using R-package enhanced volcano from Bioconductor. The resulting volcano plot identified 10 proteins with a fold change \(\geq 1.3\) and a \(p\) value \(\leq 0.05\), and identified 5 proteins with a fold change \(\leq 0.7\) and a \(p\) value \(\leq 0.05\) (Figure 2B). We then examined this list of differentially expressed proteins for those that might be candidates to regulate BMP-Smad signaling. Among this list was a protein called serine-threonine kinase receptor protein (STRAP; UniProtKB Q9Y3F4). This protein was selected for further study as the BMPRs are serine-threonine kinase receptors, and STRAP has been shown to negatively regulate TGF-\(\beta\) signaling and to positively regulate protein 3-phosphoinositide-dependent protein kinase-1 (PDK1) kinase activity by directly binding to it (Seong et al., 2005). We next identified proteins that were associated with STRAP...
Figure 2. GDF5-Induced Changes in the Proteome in SH-SY5Y Cells and Gene Co-expression Analysis of Data from the Human SN Identifies Correlated Patterns of STRAP and NME1 Expression

(A) Schema showing the experimental workflow used to identify changes in the proteome induced by GDF5 in SH-SY5Y cells.

(B) Volcano plots of the -log10p values and the log2Fold change of proteins that were altered in SH-SY5Y cells following treatment with 100 ng/mL GDF5 for 240 min.

(C–E) (C) Table showing the co-expression scores for genes associated with STRAP in STRING with a medium confidence threshold, which identified NME1 (highlighted in red), which was also found in the proteomic analyses. Graphs showing the LFQ intensities from the proteomics screen at 240 min for (D) STRAP and (E) NME1. Data are mean ± SEM from three independent samples per group (n = 3) (*p < 0.05, ***p < 0.001 versus control; Student’s t test).

(F) Linear regression showing the correlation between STRAP and NME1 in the human SN (n = 101). The r and Bonferroni-corrected p values are shown on the graph. All transcriptome data are 2log expression values. Raw data was obtained from the Gene expression Omnibus GSE60863 and analyzed using the R2 Genomics analysis and visualization platform (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi).

(G) Graph showing NME1 expression in the SN of adult rats that had received AAV-Control (“Cont”) or AAV-GDF5 (“GDF5”), as a percentage of that on the contralateral side. Data are mean ± SEM from n = 4 rats (*p < 0.05 versus control; unpaired Student’s t test).
by generating a protein-protein interaction network using STRING (https://string-db.org/) with STRAP as the hub protein. This analysis identified 29 proteins including PDPK1 (Seong et al., 2005), which confirmed the sensitivity of the approach. We then screened this list and found among it the protein nucleoside diphosphate kinase A (NME1; UniProtKB: P15531) (Figure 2C), which was also upregulated by GDF5 (Figure 2B). We next plotted the LFQ intensities of STRAP and NME1 from the LC-MS/MS proteomics data. This showed that the expression of STRAP (Figure 2D) and NME1 (Figure 2E) was significantly increased at 240 min after GDF5 treatment. We next used gene co-expression analyses, which is a recently developed approach for the analysis of cellular function based on correlated patterns of gene expression that reflect potential functional associations (Eisen et al., 1998; Homouz and Kudlicki, 2013). If STRAP and NME1 have a functional association in mDA neurons, we would expect them to display a gene co-expression pattern in the midbrain in vivo. To test this, we used available gene expression data (Gene expression Omnibus: GSE60863; Ramasamy et al., 2014), to examine whether the expression of NME1 and STRAP had a significant positive correlation in the human substantia nigra (SN). In agreement with the STRING analysis, we found that STRAP and NME1 displayed a strong positive correlation in the human SN (r = 0.845; p = 1.7 × 10^{-28}) (Figure 2F). Collectively, these data suggest a GDF5-STRAP-NME1 functional association. We also performed immunohistochemical staining on sections of adult rat brain that had been transduced with adeno-associated virus (AAV)-control or AAV-GDF5 and found increased levels of NME1 protein in dopaminergic (tyrosine hydroxylase [TH]-immunopositive) neurons within the SN of rats that had received AAV-GDF5, compared with controls (Figures 2G and 2H). This confirmed that GDF5 overexpression upregulates NME1 in vivo.

**Strap and Nme1 Are Expressed in the Developing and Adult Rodent Midbrain**

We next sought to determine whether Strap and Nme1 were expressed in the mouse midbrain in vivo. To do this, we quantified the levels of Strap and Nme1 mRNAs in the mouse ventral midbrain (VM) at intervals throughout the period of initial mDA differentiation, axon growth, and striatal innervation, and in adulthood, using quantitative real-time PCR. Strap and Nme1 displayed somewhat similar patterns of expression throughout development. Post-hoc testing showed that the expression of these mRNAs increased significantly from E10, and that Strap was maximally expressed at E12 (Figure 3A), whereas Nme1 was maximally expressed at E14 (Figure 3B). The expression levels of both mRNAs subsequently decreased from this point in development onward (Figures 3A and 3B). There was also a significant decrease in the expression of Strap and Nme1 from P5 to P90 (Figures 3A and 3B). In situ hybridization data from the Allen Mouse Brain Atlas confirmed the co-localization of Strap (Figure 3C) and Nme1 (Figures 3D and 3F) transcripts with the expression of the mDA markers, Girk2 and Aldh1a1 (Figures 3E and 3G), in adult mouse substantia nigra pars compacta (SNpc). To verify that these proteins are co-expressed in adult rat SN, we performed immunohistochemical staining, which showed that Nme1 was expressed in adult rat SN, in all TH-immunopositive neurons (Figure 3H). This confirms the expression of NME1 in adult mDA neurons.

**Gene Co-expression Analysis of Human SN Identifies STRAP and NME1 Co-expression with Multiple Markers of Midbrain Dopaminergic Neurons**

Building on the analyses of the mouse brain, we next investigated whether STRAP and NME1 were co-expressed with multiple markers of mDA neurons in the human SN. To investigate this, we again used available gene expression data from the Gene expression Omnibus (GSE60863) to determine if STRAP and NME1 displayed any significant positive correlation with the expression of three markers of mDA neurons: TH, G-protein-regulated inward rectifier potassium channel (GIRK) 2, and aldehyde dehydrogenase (ALDH) 1A1. Both STRAP and NME1 were found to have a significant positive correlation with all three mDA markers. These data show that transcripts for STRAP (Figure 4A) and NME1 (Figure 4B) display a positive co-expression pattern with transcripts for multiple markers of mDA neurons in the human SN, suggesting that they may play a functional role in mDA neurons. To gain some insight into this, we next identified all genes that had a significant positive correlation with transcripts for STRAP and NME1 in the human SN (Figure 4C). A gene ontology (GO) enrichment analysis revealed that the GO category “Neurofilament cytoskeletal organisation” (Figure 4C) was among the top two GO categories overrepresented in the lists of genes that displayed a co-expression pattern with STRAP and NME1. As “Neurofilament cytoskeletal organisation” was the common ontology of both STRAP and NME1, we examined the co-expression of NME1 with these markers.
and STRAP with all genes annotated for this ontology in the human SN. The results showed significant positive correlation between the expression of NME1 and STRAP with Internexin neuronal intermediate filament protein alpha (INA), Neurofilament heavy (NEFH), ATPase phospholipid transporting 8A2 (ATP8A2), Neurofilament light (NEFL), superoxide dismutase 1 (SOD1), and NudE neurodevelopment protein 1 like 1 (NEDL1) (Table 1). Collectively, these data show that STRAP and NME1 are expressed in the mouse and human SN, and suggest that STRAP and NME1 may regulate neurite growth and/or the neurite growth-promoting effects of GDF5.

STRAP and NME1 Are Necessary for Basal and GDF-5-Induced Neurite Growth in SH-SY5Y Cells

To test the above-mentioned hypothesis, we next used neurite outgrowth as a phenotypic readout to examine the effect of small interfering RNAs (siRNAs) against STRAP and NME1 in individual cells. To do this, we transfected SH-SY5Y cells with 25 nM of a scrambled siRNA (siSCR) or siRNAs targeting STRAP (si-STRAP) or NME1 (siNME1) together with a GFP expression plasmid to identify transfected cells, which led to a significant reduction in cellular NME1 expression (Figure 5A). Following transfection, the cells were cultured with or without 100 ng/mL GDF5 and neurite growth was analyzed at 72 h. Transfection with
siSTRAP led to a significant reduction in neurite growth compared with siSCR control (51.5% versus 6.5% of the siSCR control) (Figure 5B). GDF5 treatment led to a significant increase in neurite growth in cells transfected with the siSCR (p < 0.001; 135.1% of the control) (Figure 5B). In contrast, neurite growth in cells transfected with siSTRAP and cultured with GDF5 was significantly reduced compared with siSCR alone (p < 0.01), and siSTRAP completely prevented the neurite growth-promoting effects of GDF5 (siSTRAP: 51.5% versus siSTRAP + GDF5: 50.7%). Similarly, transfection with siNME1 led to a significant reduction in neurite growth compared with siSCR control (59.5% of the control). In contrast, neurite growth in cells transfected with siNME1 and cultured with GDF5 was significantly reduced compared with the siSCR group, and siNME1 completely prevented the effects of GDF5 on neurite growth (siNME1: 59.5% versus siNME1 + GDF5: 62.1%).

Overexpression of STRAP or NME1 Is Sufficient to Promote Neurite Growth in SH-SYSY Cells
Given that siRNA targeting NME1 or STRAP reduced neurite growth, we next examined whether NME1 and STRAP overexpression could promote neurite growth. To do this, we transfected SH-SYSY cells with plasmids overexpressing Myc-tagged NME1 or STRAP, while a GFP-expressing plasmid was used as a control. This resulted in significant overexpression of NME1 protein (Figure 6A). Following transfection, the cells were cultured with or without 100 ng/mL GDF5 and neurite growth was analyzed at 36 h post-transfection. NME1 overexpression led to a significant increase in neurite growth at 36 h (218.5% versus...
control), with or without GDF5 (Figure 6B). Similarly, overexpression of STRAP led to a significant increase in neurite growth (166.7% versus control) with or without GDF5 (Figure 6B). The ability of overexpressed NME1 or STRAP to promote neurite growth persisted to 72 h in culture (Figure 6C). Collectively, these data show that STRAP and NME1 are both necessary and sufficient for basal and GDF5-promoted neurite growth.

Recombinant NME1 Increases Neurite Growth in SHSY5Y Cells and in Cultured E14 Rat mDA Neurons

Overexpression of NME1 was found to significantly increase neurite length in SH-SY5Y cells. We further tested whether treatment of SH-SY5Y cells and cultured E14 rat mDA neurons with recombinant human NME1 would also increase neurite length. Treatment of SH-SH5Y cells for 48 h with 100 or 200 ng/mL recombinant NME1 resulted in significant increases in neurite length (Figure 7A), as did treatment for 48 h of cultured E14 mDA neurons with 100 ng/mL recombinant NME1 (Figures 7B and 7C).

Alterations in the Expression of STRAP and NME1 in the PD SN

Finally, we analyzed data from age- and gender-matched samples available in the Gene Expression Omnibus: GSE49036 (Dijkstra et al., 2015) to examine NME1 and STRAP expression, as well as co-expression patterns in the SN, of patients with PD at Braak stage 5/6 (n = 8), and of control subjects (n = 8) (Figure 8A). As expected, there was significant lower expression of the mDA neuron marker ALDH1A1 in PD samples compared with controls, which validated the approach (Figure 8B). Although there was a trend toward a decrease in STRAP expression in PD samples, this did not reach statistical significance (Figure 8C). However, there was a statistically significant downregulation of NME1 in the SN of patients with PD compared with controls (Figure 8D). We also examined the co-expression pattern of STRAP and NME1 with ALDH1A1 in these PD and control SN samples. The rationale for doing this is that in a range of diseases, normal co-expression patterns tend to break down, and these broken correlations can be used as an index of functional misregulation (Torkamani et al., 2010; Zhang et al., 2013; Southworth et al., 2009). In agreement with our earlier analyses, we found that both STRAP (r = 0.869, p = 5.07 × 10^{-5}) (Figure 8E) and NME1 (r = 0.867, p = 5.31 × 10^{-5}) (Figure 8G) showed significant positive correlation with ALDH1A1 in the controls. In contrast, there was no positive correlation of both STRAP (r = 0.500, p = 0.207) and NME1 (r = 0.516, p = 0.191) with ALDH1A1 in PD SN samples (Figures 8F and 8H). These broken correlations suggest a functional misregulation of STRAP-NME1 in PD.

Table 1. List of Genes Annotated for GO:0060052 (Neurofilament Cytoskeletal Organisation) which Are Co-expressed with NME1 and STRAP

| Ensemble Gene ID | Gene Symbol | Description | Co-expression with NME1 | Co-expression with STRAP |
|------------------|-------------|-------------|-------------------------|-------------------------|
| ENSG00000148798  | INA         | Internexin neuron intermediate filament protein alpha | r = 0.892, p = 5.12 × 10^{-32} | r = 0.719, p = 2.12 × 10^{-13} |
| ENSG00000100285  | NEFH        | Neurofilament heavy | r = 0.862, p = 4.39 × 10^{-27} | r = 0.798, p = 1.47 × 10^{-19} |
| ENSG00000132932  | ATP8A2      | ATPase phospholipid transporting 8A2 | r = 0.872, p = 1.54 × 10^{-28} | r = 0.760, p = 2.68 × 10^{-16} |
| ENSG00000277586  | NEFL        | Neurofilament light | r = 0.890, p = 1.60 × 10^{-31} | r = 0.740, p = 8.14 × 10^{-15} |
| ENSG00000142168  | SOD1        | Superoxide dismutase 1 | r = 0.909, p = 1.53 × 10^{-35} | r = 0.850, p = 2.32 × 10^{-25} |
| ENSG00000166579  | NDEL1       | NudE neurodevelopment protein 1 like 1 | r = 0.895, p = 1.71 × 10^{-32} | r = 0.748, p = 2.21 × 10^{-15} |

control, with or without GDF5 (Figure 6B). Similarly, overexpression of STRAP led to a significant increase in neurite growth (166.7% ± 11.1% versus control) with or without GDF5 (Figure 6B). The ability of overexpressed NME1 or STRAP to promote neurite growth persisted to 72 h in culture (Figure 6C). Collectively, these data show that STRAP and NME1 are both necessary and sufficient for basal and GDF5-promoted neurite growth.

Recombinant NME1 Increases Neurite Growth in SHSY5Y Cells and in Cultured E14 Rat mDA Neurons

Overexpression of NME1 was found to significantly increase neurite length in SH-SY5Y cells. We further tested whether treatment of SH-SY5Y cells and cultured E14 rat mDA neurons with recombinant human NME1 would also increase neurite length. Treatment of SH-SH5Y cells for 48 h with 100 or 200 ng/mL recombinant NME1 resulted in significant increases in neurite length (Figure 7A), as did treatment for 48 h of cultured E14 mDA neurons with 100 ng/mL recombinant NME1 (Figures 7B and 7C).

Alterations in the Expression of STRAP and NME1 in the PD SN

Finally, we analyzed data from age- and gender-matched samples available in the Gene Expression Omnibus: GSE49036 (Dijkstra et al., 2015) to examine NME1 and STRAP expression, as well as co-expression patterns in the SN, of patients with PD at Braak stage 5/6 (n = 8), and of control subjects (n = 8) (Figure 8A). As expected, there was significant lower expression of the mDA neuron marker ALDH1A1 in PD samples compared with controls, which validated the approach (Figure 8B). Although there was a trend toward a decrease in STRAP expression in PD samples, this did not reach statistical significance (Figure 8C). However, there was a statistically significant downregulation of NME1 in the SN of patients with PD compared with controls (Figure 8D). We also examined the co-expression pattern of STRAP and NME1 with ALDH1A1 in these PD and control SN samples. The rationale for doing this is that in a range of diseases, normal co-expression patterns tend to break down, and these broken correlations can be used as an index of functional misregulation (Torkamani et al., 2010; Zhang et al., 2013; Southworth et al., 2009). In agreement with our earlier analyses, we found that both STRAP (r = 0.869, p = 5.07 × 10^{-5}) (Figure 8E) and NME1 (r = 0.867, p = 5.31 × 10^{-5}) (Figure 8G) showed significant positive correlation with ALDH1A1 in the controls. In contrast, there was no positive correlation of both STRAP (r = 0.500, p = 0.207) and NME1 (r = 0.516, p = 0.191) with ALDH1A1 in PD SN samples (Figures 8F and 8H). These broken correlations suggest a functional misregulation of STRAP-NME1 in PD.
DISCUSSION

GDF5 is a neurotrophic factor that has been shown to protect mDA neurons from neurotoxic insults in vitro and in vivo (Sullivan et al., 1997, 1998; Hurley et al., 2004; Toulouse et al., 2012; Costello et al., 2012). In addition, it is well established that GDF5 promotes neurite growth in SH-SY5Y cells and in cultured rodent mDA neurons (O’Keeffe et al., 2004a, 2004b; Hegarty et al., 2013, 2014), enhances neurite complexity in cultured murine hippocampal neurons (Osorio et al., 2013), and increases axonal growth in mouse superior cervical ganglial cells in vitro (O’Keeffe et al., 2016). The effects of GDF5 on mDA neurons are dependent on BMPR1B and Smad signaling (Hegarty et al., 2014; Hegarty et al., 2018), whereas the downstream changes
that mediate the neurotrophic effects of GDF5 on mDA neurons are unknown. This is important because GDF5 has been proposed as a candidate neurotrophic factor for therapeutic application in PD (O’Keeffe et al., 2017; Paul and Sullivan, 2018), where a characteristic feature is axonal degeneration (Burke and O’Malley, 2013; O’Keeffe and Sullivan, 2018).

In neuronal populations other than mDA neurons, it has been demonstrated that GDF5 can regulate dendritic size and complexity through the upregulation and recruitment of HESS transcription factor (Osorio et al., 2013). That study also showed that, during development, GDF5 null mice displayed impairments in dendritic growth from hippocampal pyramidal cells (Osorio et al., 2013). Another study, which examined
the role of Dachshund family transcription factor (DACH) 2-histone deacetylase (HDAC) 9 signaling in re-innervation of muscle endplates, showed that HDAC9 regulates GDF5 expression to enhance motor functioning by promoting innervation in disrupted neuromuscular junctions (Macpherson et al., 2015). In the present study, in agreement with past work from our group (Hegarty et al., 2013), we show that in the SH-SY5Y cell line, GDF5 activates the BMP-Smad pathway by phosphorylation of Smad1/5/9 and its subsequent nuclear localization. We also found that, similar to the situation in cultured hippocampal neurons (Osorio et al., 2013), GDF5 treatment results in upregulation of Hes5 and Zeb2 mRNA in SH-SY5Y cells. We used this model to perform proteomic analysis, investigating the downstream changes in protein expression that are required for the effects of GDF5 on neurite growth in SH-SY5Y cells. This analysis revealed significant upregulation of two proteins, known as STRAP and NME1, in GDF5-treated cells. Furthermore, we examined the SN from the brains of adult rats that had received intranigral AAV-GDF5 and found increased levels of NME1 protein compared with controls. This establishes that GDF5-mediated increases in NME1 protein levels occur not only in SH-SH5Y cells but also are found in the adult rat brain in vivo.

NME1 is a protein that possesses serine/threonine-specific protein kinase activity and plays a role in neural development; it has been reported to be downregulated in the SN of patients with PD, in a study of genes related to purine metabolism (García-Esparcia et al., 2015). NME1 is also known to physically interact with STRAP and to negatively regulate TGFβ-mediated signaling (Seong et al., 2007). We used gene co-expression analysis to show that STRAP and NME1 had a strong co-expression pattern in the human SN, which suggests a functional association between these two proteins. STRAP was initially isolated from HeLa cells, as a component of survival of motor neuron complex (SMN) (Meister et al., 2001), and is known to co-localize with SMN complex components in neurite projections formed in nerve growth factor (NGF)-treated PC12 cells (Sharma et al., 2005). NME1 has been reported to play several roles in neuronal growth, and it is known to play a role in fate determination of glial progenitor cells, directing them toward a neuronal fate (Owlanj et al., 2012). These findings suggest roles for NME1 and STRAP in neuronal growth and development. In support of this, we observed a significant increase in the expression of transcripts for STRAP and NME1 in the mouse VM between E12 and E14, which is the period of maximal axonal outgrowth of mDA neurons toward their striatal targets. Consistent with this, NME1 is known to be expressed, and to interact with prune exopolyphosphatase (PRUNE1), in the midbrain and SN of E14.5 mice (Carotenuto et al., 2006). We also report that STRAP and NME1 are both expressed in the SNpc of adult mice. Furthermore, we found that NME1 and TH were co-expressed in mDA neurons in the adult rat SN, further validating our gene co-expression data. Collectively, these data suggest that STRAP and NME1 play roles in the development and growth of nigrostriatal dopaminergic neurons.

In our study, the expression of both STRAP and NME1 exhibited strong positive correlation with that of TH, GIRK2, and ALDH1A1, all of which are markers of mDA neurons. Subsequently, we performed a gene ontology enrichment analysis of all the genes that are co-expressed with STRAP in the human SN. We observed that genes that were co-expressed with STRAP were involved in processes such as postsynaptic...
intermediate filament cytoskeleton organization and neurofilament cytoskeleton organization. We then obtained a list of all genes that are co-expressed with NME1 in the human SN and performed a GO analysis on these. We found that processes that were significantly enriched included circadian sleep/wake cycle and neurofilament cytoskeleton organization. Further analysis of those genes involved in neurofilament cytoskeleton organization in the human SN showed strong correlation between the expression of both NME1 and STRAP and that of several key proteins that are involved in cytoskeletal processes, namely, INA, NEFH, ATP8A2, NEFL, SOD1, and NudE NED1.

Together, these data suggest that NME1 and STRAP are involved in GDF5-mediated neurite growth. In agreement with this, we found that silencing of NME1 resulted in impaired neurite growth in SH-SH5Y cells, a process that is used as a marker of neural differentiation. Furthermore, treatment of SH-SH5Y cells with GDF5 had no effect on neurite growth when NME1 was silenced. Given these data, we propose that NME1 is an essential downstream effector of GDF5-induced enhancement of neurite growth. Moreover, we found that NME1 overexpression was sufficient to promote axon growth, and that treatment with recombinant NME1 protein significantly increased neurite outgrowth in both SH-SY5Y cells and cultured mDA neurons.

We also found that silencing of STRAP impaired basal and GDF5-promoted neurite growth, and that STRAP overexpression promoted neurite growth in SH-SYSY cells. To our knowledge, this is the first report of a function for STRAP in the regulation of axonal growth. A proteome analysis study found that STRAP protein
levels are regulated during the differentiation of the human fetal midbrain stem cell line, ReNcell VM (Hoffrogge et al., 2006); this suggests that regulation of STRAP expression may be associated with cellular differentiation. It is well characterized that STRAP inhibits apoptosis by directly interacting with apoptosis signal-regulating kinase (ASK)1 (Jung et al., 2010). As there is increased apoptosis and axonal degeneration in the PD brain, GDF5-mediated upregulation of STRAP protein levels in the brain may be involved in the neuroprotective effects of this factor. Furthermore, it is known that STRAP interacts with TGFβ-interacting protein and that phosphorylation of STRAP at its Ser188 residue by serine/threonine kinase 38 (MPK38) is important for the pro-apoptotic function of STRAP (Seong et al., 2014). As many kinases are known to play roles in PD neuropathology, STRAP inhibition may provide a new therapeutic approach for slowing the progression of PD.

Our analysis of datasets of gene expression in PD and control SN found that the expression of NME1 was significantly lower in the PD brain. In addition, there was a loss of the normal co-expression pattern of NME1 with the mDA marker, ALDHA1A, in PD patient samples. It has been well-documented that normal gene co-expression patterns are disrupted in disease states, and that these broken correlations can be used as an index of functional misregulation (Torkamani et al., 2010; Zhang et al., 2013; Southworth et al., 2009). NME1 expression has also reported to be downregulated in Alzheimer disease (Cieślak and Wojtczak, 2018). GDF5-mediated increases in NME1 levels could potentially be applied to address the loss in NME1 expression, and to restore its co-expression profile in mDA neurons, with the aim of conferring neuroprotection in PD.

STRAP expression was slightly, although not significantly, reduced in the PD brain, whereas its co-expression with ALDHA1A was significantly impaired. Such loss of co-expression in PD may reflect a role for STRAP in endogenous protective mechanisms in the brain, which may be adversely affected by PD pathology. It is known that STRAP has antiapoptotic effects (Jung et al., 2010) and that it can regulate the heat shock protein (HSP) response by acting as a modulator of p300 (Xu et al., 2008). As HSP signaling is thought to be a crucial cytoprotective mechanism in PD (Luo et al., 2006), GDF5-mediated upregulation of STRAP might confer a neuroprotective effect, in addition to its role in increasing neurite growth. This loss of STRAP/ALDHA1A co-expression in PD could potentially be rescued by GDF5 treatment, which may be sufficient to restore levels of STRAP in mDA neurons.

Activation of the BMP-Smad pathway by the GDF5-related factor BMP2 has been found to restore neurite growth in 1-methyl-4-phenylpyridinium (MPP⁺), 6-OHDA- and α-synuclein-induced in vitro models of PD (Goulding et al., 2019). Delivery of neurotrophic proteins such as GDF5 and BMP2 to the PD brain is associated with issues due to their large size and rapid metabolism, thus strategies aimed at manipulation of their downstream signaling molecules would be advantageous. The discovery in the present study that GDF5 treatment induced increases in neurite growth through the regulation of NME1 and STRAP proteins rationalizes the further study of NME1 and STRAP as potential neuroprotective targets that may be useful for therapies aimed at axonal regeneration in PD.

Limitations of the Study

In our current study, we used SH-SYSY cells as a model of dopaminergic neurons rather than primary cultures of dopaminergic neurons. This was to ensure a homogeneous population of cells for proteome analysis, rather than mixed cell cultures of embryonic rat midbrain tissue. Furthermore, SH-SYSY cells express several markers of dopaminergic neurons, and are a widely used in vitro model for the study of molecular signaling of relevance to PD.

Resource Availability

Lead Contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Gerard O’Keeffe (g.okeeffe@ucc.ie).

Materials Availability

All unique/stable reagents generated in this study are available from the Lead Contact without restriction.
Data and Code Availability
The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.101457.

ACKNOWLEDGMENTS
This publication has emanated from research conducted with the financial support of a research grant from Science Foundation Ireland (Grant number: 15/CDA/3498) (G.W.O.K.).

AUTHOR CONTRIBUTIONS
J.A. carried out the proteome and cell culture experiments. S.R.G. carried out the histology experiments and quantification. R.M.C. performed stereotactic surgery. S.L.W. carried out the RT-qPCR. G.W.O.K. carried out the gene co-expression analysis. J.A., S.R.G., S.L.W., A.M.S., and G.W.O.K. analyzed the data, prepared the figures and wrote the manuscript. All authors edited the final manuscript. A.M.S. and G.W.O.K. designed the study and supervised the work.

DECLARATION OF INTERESTS
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: April 3, 2020
Revised: July 17, 2020
Accepted: August 10, 2020
Published: September 25, 2020

REFERENCES
Burke, R.E., and O’Malley, K. (2013). Axon degeneration in Parkinson’s disease. Exp. Neurol. 246, 72–83.
Caminiti, S.P., Presotto, L., Baroncini, D., Garibotto, V., Moresco, R.M., Gianalli, L., Volonte, M.A., Antonini, A., and Perani, D. (2017). Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson’s disease. Neuroimage. Clin. 14, 734–740.
Carotenuto, P., Marino, N., Bello, A.M., D’Angelo, A., Di Porzio, U., Lombardi, D., and Zollo, M. (2006). PRUNE and NM23-M1 expression in embryonic and adult mouse brain. J. Bioenerg. Biomembr. 38, 233–246.
Cieślak, M., and Wójcicka, A. (2018). Role of purinergic receptors in the Alzheimer’s disease. Purinergic Signal. 14, 331–344.
Costello, D.J., O’Keeffe, G.W., Hurley, F.M., and Sullivan, A.M. (2012). Transplantation of novel human GDF5-expressing CHO cells is neuroprotective in models of Parkinson’s disease. J. Cell Mol. Med. 16, 2451–2460.
Decressac, M., Kadkhodaei, B., Mattsson, B., Laguna, A., Perlmann, T., and Björklund, A. (2012). α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci. Transl. Med. 4, 163ra156.
Dijkstra, A.A., Ingrassia, A., de Menezes, R.X., van Kesteren, R.E., Rozenmuller, A.J., Heutink, P., and van der Berg, W.D. (2015). Evidence for immune response, axonal dysfunction and reduced endocytosis in the substantia nigra in early stage Parkinson’s disease. PLoS One 10, e0128651.
Drinkut, A., Tillack, K., Meka, D.P., Schulz, J.B., Kugler, S., and Kramer, E.R. (2016). Ret is essential to mediate GDNF’s neuroprotective and neuroregenerative effect in a Parkinson disease mouse model. Cell Death Dis. 7, e2359.
Eisen, M.B., Spellman, P.T., Brown, P.O., and Botstein, D. (1998). Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U S A 95, 14863–14868.
Garcia-Esparcia, P., Hernández-Ortega, K., Ansoleaga, B., Carmona, M., and Ferrer, I. (2015). Purine metabolism gene deregulation in Parkinson’s disease. Neuropathol. Appl. Neurobiol. 41, 926–940.
Gavin, A.M., Walsh, S., Wyatt, S., O’Keeffe, G.W., and Sullivan, A.M. (2014). 6-Hydroxydopamine induces distinct alterations in GDF5 and GDNF mRNA expression in the rat nigrostriatal system in vivo. Neurosci. Lett. 567, 176–181.
Gill, S.S., Patel, N.K., Hotton, G.R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D.J., Svendsen, C.N., and Heywood, F. (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9, 589–595.
Goulding, S.R., Sullivan, A.M., O’Keeffe, G.W., and Collins, L.M. (2019). Gene co-expression analysis of the human substantia nigra identifies BMP2 as a neurotrophic factor that can promote neurite growth in cells overexpressing wild-type or AS3T α-synuclein. Parkinsonism Relat. Disord. 64, 194–201.
Hegarty, S.V., Sullivan, A.M., and O’Keeffe, G.W. (2013). BMP2 and GDF5 induce neuronal differentiation through a Smad dependent pathway in a model of human midbrain dopaminergic neurons. Mol. Cell Neurosci. 56, 263–271.
Hegarty, S.V., Collins, L.M., Gavin, A.M., Roche, S.L., Wyatt, S.L., Sullivan, A.M., and O’Keeffe, G.W. (2014). Canonical BMP-Smad signalling promotes neurite growth in rat midbrain dopaminergic neurons. Neuromolecular Med. 16, 473–489.
Hegarty, S.V., Sullivan, A.M., and O’Keeffe, G.W. (2018). Inhibition of miR-181a promotes midbrain
neuronal growth through a Smad1/5-dependent mechanism: implications for Parkinson’s disease. Neuronal Signal. 2. NS20170181. https://doi.org/10.1042/NS20170181.

Hegarty, S.V., Wyatt, S.L., Howard, L., Stappers, E., Hyle Hoebroek, D., Sullivan, A.M., and O’Keeffe, G.W. (2017). Zeb2 is a negative regulator of midbrain dopaminergic axon growth and target innervation. Sci. Rep. 7, 8568.

Hoffrogge, R., Mikkat, S., Scharf, C., Beyer, S., Christoph, H., Fahnke, J., Mix, E., Berth, M., Uhrmacher, A., Zubrzycki, J., et al. (2006). Z-DE proteome analysis of a proliferating and differentiating human neuronal stem cell line (ReNeuCL VM). Proteomics 6, 1833–1847.

Homouz, D., and Kudlicki, A.S. (2013). The 3D organization of the yeast genome correlates with co-expression and reflects functional relations between genes. PLoS One 8, e54699.

Hurley, F.M., Costello, D.J., and Sullivan, A.M. (2004). Neuroprotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinson’s disease. Exp. Neurol. 185, 281–289.

Jaumotte, J.D., and Zigmund, M.J. (2014). Comparison of GDF5 and GDNF as neuroprotective factors for postnatal dopamine neurons in ventral mesencephalic cultures. J. Neurosci. Res. 92, 1425–1433.

Jung, H., Seong, H.-A., Manoharan, R., and Ha, H. (2010). Serine-threonine kinase receptor-associated protein inhibits apoptosis signal-regulating kinase 1 function through direct interaction. J. Biol. Chem. 285, 54–70.

Kelly, M.J., O’Keeffe, G.W., and Sullivan, A.M. (2015). Viral vector delivery of neurotrophic factors for Parkinson’s disease therapy. Expert Rev. Mol. Med. 17, e8.

Kriegstein, K., and Unsicker, K. (1995). Bovine chromaffin cells release a transforming growth factor-β-like molecule contained within chromaffin granules. J. Neurochem. 65, 1423–1426.

Lang, A.E., Gill, S., Patel, N.K., Lozano, A., Nutt, J.G., Penn, R., Brooks, D.J., Hotton, G., Moro, E., Heywood, P., et al. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor-containing virus serotype 2-neurturin to patients with idiopathic Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9, 1164–1172.

Marks, W.J. Jr., Bartus, R.T., Sifert, J., Davis, C.S., Lozano, A., Boulis, N., Vetek, J., Stacy, M., Turner, D., Verghese, L., et al. (2010). Gene delivery of AVV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9, 1164–1172.

Meister, G., Bühler, D., Pillar, R., Lottspeich, F., and Fischer, U. (2001). A multiprotein complex mediates the ATP-dependent assembly of spliceosomal U snRNPs. Nat. Cell Biol. 3, 945–949.

O’Keeffe, G.W., Dockery, P., and Sullivan, A.M. (2004). Effects of growth/differentiation factor-5 on the survival and morphology of embryonic rat midbrain dopaminergic neurones in vitro. J. Neurocytol. 33, 479–488.

O’Keeffe, G.W., Gutierrez, H., Howard, L., Laurie, C.W., Osorio, C., Gavalda, N., Wyatt, S.L., and Davies, A.M. (2016). Region-specific role of growth differentiation factor-5 in the establishment of sympathetic innervation. Neural Dev. 11, 4. https://doi.org/10.1186/s13016-016-0060-3.

O’Keeffe, G.W., Hanke, M., Pohl, J., and Sullivan, A.M. (2004b). Expression of growth differentiation factor-5 in the developing and adult rat brain. Brain Res. Dev. Brain Res. 151, 199–202.

O’Keeffe, G.W., Hegarty, S.V., and Sullivan, A.M. (2017). Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson’s disease. Neuronal Signal. 7, NS20170027. https://doi.org/10.1042/NS20170027.32714578.

O’Keeffe, G.W., and Sullivan, A.M. (2018). Evidence for dopaminergic axonal degeneration as an early pathologic process in Parkinson’s disease. Parkinsonism Relat. Disord. 56, 9–15.

Osorio, C., Chacon, P.J., Kississa, L., White, M., Wyatt, S., Rodriguez-Tebar, A., and Davies, A.M. (2013). Growth differentiation factor 5 is a key physiological regulator of dendrite growth during development. Development 140, 4751–4762.

Owlanj, H., Jie Yang, H., and Wei Feng, Z. (2012). Nucleoside diphosphate kinase Nmnat5-M1 involves in allogendroglial versus neuronal cell fate decision in vitro. Differentiation 84, 281–293.

Paul, G., and Sullivan, A.M. (2018). Trophic factors for Parkinson’s disease: where are we and where do we go from here? Eur. J. Neurosci. 49, 440–452.

Ramasamy, A., Trabzuni, D., Guelfi, S., Varghese, V., Smith, C., Walker, R., De, T., Consortium, U.K.B.E., North American Brain Expression, C., Corsi, L., et al. (2014). Genetic variability in the regulation of gene expression in ten regions of the human brain. Nat. Neurosci. 17, 1418–1428.

Seong, H.A., Jung, H., Choi, H.S., Kim, K.T., and Ha, H. (2005). Regulation of transforming growth factor-beta signaling and PDK1 kinase activity by physical interaction between PDK1 and serine-threonine kinase receptor-associated protein. J. Biol. Chem. 280, 42897–42908.

Seong, H.A., Jung, H., and Ha, H. (2007). NM23-H1 tumor suppressor suppresses growth of human glioblastoma cells through interaction of serine/threonine kinase receptor-associated protein, a transforming growth factor-beta (TGF-beta) receptor-interacting protein, and negatively regulates TGF-beta signaling. J. Biol. Chem. 282, 12075–12096.

Seong, H.A., Manoharan, R., and Ha, H. (2014). A crucial role for the phosphorylation of STRAP at Ser188 by MKP3 in STRAP-dependent cell death through ASK1, TGF-β, p53, and PI3K/PDK1 signaling pathways. Cell Cycle 13, 3357–3374.

Sharma, A., Lambrecht, A., Hao, L.T., Le, T.T., Sewry, C.A., Ampe, C., Burghes, A.H.M., and Morris, G.E. (2005). A role for complexes of survival motor neuron (SMN) protein with gemins and profilin in neurite-like cytoplasmic extensions of cultured nerve cells. Exp. Cell Res. 309, 185–197.

Slevin, J.T., Gash, D.M., Smith, C.D., Gerhardt, G.A., Kyscio, R., Chebrolu, H., Walton, A., Wagner, R., and Young, A.B. (2007). Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J. Neurosurg. 106, 614–620.

Southworth, L.K., Owen, A.B., and Kim, S.K. (2009). Aging mice show a decreasing correlation of gene expression within genetic modules. PLoS Genet. 5, e1000776.

Storm, E.E., Huyhn, T.V., Copeland, N.G., Jenkins, N.A., Kingsley, D.M., and Lee, S.J. (1994). Limb alterations in brachypodism mice due to mutations in a new member of the TGF beta-superfamily. Nature 368, 639–643.

Storm, E.E., and Kingsley, D.M. (1996). Joint patterning defects caused by single and double mutations in members of the bone morphogenetic protein (BMP) family. Development 122, 3969–3979.

Sullivan, A.M., Opacka-Juffry, J., Hotten, G., Pohl, J., and Blunt, S.B. (1997). Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson’s disease. Neurosci. Lett. 233, 73–76.

Sullivan, A.M., Pohl, J., and Blunt, S.B. (1998). Growth/differentiation factor 5 and glial cell line-
derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson’s disease. Eur. J. Neurosci. 10, 3681–3688.

Sullivan, A.M., and O’Keefe, G.W. (2016). Neurotrophic factor therapy for Parkinson’s disease: past, present and future. Neural Regen. Res. 11, 205–207.

Torkamani, A., Dean, B., Schork, N.J., and Thomas, E.A. (2010). Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Res. 20, 403–412.

Toulouse, A., Collins, G.C., and Sullivan, A.M. (2012). Neurotrophic effects of growth/differentiation factor 5 in a neuronal cell line. Neurotoxicity Res. 21, 256–265.

Tysnes, O.-B., and Storstein, A. (2017). Epidemiology of Parkinson’s disease. J. Neural Transm. 124, 901–905.

Warren Olanow, C., Bartus, R.T., Baumann, T.L., Factor, S., Boulis, N., Stacy, M., Turner, D.A., Marks, W., Larson, P., Starr, P.A., et al. (2015). Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann. Neurol. 78, 248–257.

Whone, A., Luz, M., Boca, M., Woolley, M., Mooney, L., Dhana, S., Broadfoot, J., Cronin, D., Schroers, C., Barua, N.U., et al. (2019). Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease. Brain 142, 512–525.

Wright, K.T., Seabright, R., Logan, A., Lilly, A.J., Khami, F., Bunce, C.M., and Johnson, W.E.B. (2010). Extracellular Nm23R1 stimulates neurite outgrowth from dorsal root ganglia neurons in vitro independently of nerve growth factor supplementation or its nucleoside diphosphate kinase activity. Biochem. Biophys. Res. Commun. 398, 79–85.

Xicoy, H., Wieringa, B., and Martens, G.J.M. (2017). The SH-SYSY cell line in Parkinson’s disease research: a systematic review. Mol. Neurodegener. 12, 1–11.

Xu, D., Zalmas, L.P., and La Thangue, N.B. (2008). A transcription cofactor required for the heat-shock response. EMBO Rep. 9, 662–669.

Zhang, B., Gaiteri, C., Bodea, L.G., Wang, Z., McElwee, J., Podtelezhnikov, A.A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013). Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell 153, 707–720.
Supplemental Information

STRAP and NME1 Mediate the Neurite Growth-Promoting Effects of the Neurotrophic Factor GDF5

Jayanth Anantha, Susan R. Goulding, Sean L. Wyatt, Ruth M. Concannon, Louise M. Collins, Aideen M. Sullivan, and Gerard W. O'Keeffe
SUPPLEMENTAL INFORMATION.

TRANSPARENT METHODS

**Cell culture and treatment.** SH-SY5Y cells were grown in DMEM-high glucose (D5796) supplemented with 10% (v/v) FBS, 1% (v/v) glutamine (G7513), 1% (v/v) non-essential amino acids (M7145), 1% (v/v) sodium pyruvate (S8636), and 1% (v/v) penicillin/streptomycin (P4333) (all from Sigma). Cells were cultured at 37°C with 5% CO₂. For Western blotting and RNA extraction, 2.5x10⁶ SH-SY5Y cells were plated overnight on a 6-well plate and treated with 100ng/ml of GDF5 (Preprotech; Cat no.120-01) for 0 to 240 min. For analysis of neurite length, 30,000-50,000 SH-SY5Y cells were plated overnight on a 24-well plate and treated with 100 ng/ml GDF5 for 72h, or with 10, 50, 100 or 200 ng/ml of recombinant human NME1 (Novus Biological; Cat no. NBP2-252250) for 48 h. Primary cultures of E14 rat VM were prepared as described in Hegarty et al., 2014. In brief, E14 embryos were obtained from date-mated Sprague-Dawley rats under terminal anaesthesia using isoflurane. Dissected VM tissue was centrifuged at 1100 rpm for 5 min at 4°C. The tissue pellet was incubated in 0.1% trypsin-Hank’s Balanced Salts solution for 5 min at 37°C with 5% CO₂. Following addition of fetal calf serum and centrifugation at 1100 rpm for 5 min at 4°C, the resulting cell pellet was resuspended in 1 ml of differentiation media (Dulbecco's modified Eagle's medium/F12, 33 mM D-glucose, 1% L-glutamine, 1% FCS, supplemented with 2% B27) and triturated. Cells were plated on poly-D-lysine (Sigma)-coated 24-well tissue culture plates at a density of 5 x 10⁴ cells per well in 500 μl of differentiation media at 37°C with 5% CO₂. Cultures were treated with 100 ng/ml recombinant human NME1 for 48 h.

**Western blotting.** Cells were lysed in RIPA buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) supplemented with 1 mM sodium orthovanadate, 1mM fluoride and complete protease inhibitor cocktail, as per the manufacturer’s recommendation (Roche Molecular Biochemicals; 11836170001) for 30 min on ice. Lysates were centrifuged at 13,000 rpm for 20 min at 4°C and the supernatant was transferred into a fresh tube. The protein concentration of the samples was determined using the BCA method (Pierce; Cat no. 23227) and stored at -20°C prior to analysis. Upon use, lysates were mixed with a 1x sample loading buffer (SLB) (5xSLB-containing 70ml glycerol 30ml water with 0.2g of bromophenol blue, 2.5g sodium dodecyl sulphate, 0.606g of Tris base with 5-6% v/v β-mercaptoethanol) and boiled at 95°C for 5-10 min. The samples were then resolved on a SDS-PAGE gel and transferred to a PVDF membrane. The membrane was blocked in blocking buffer (containing 5% BSA and 0.1% Tween20 in 1xPBS/1xTBS) for 1 h at room temperature, then sequentially probed with primary and the appropriate HRP-linked secondary antibodies made up in blocking buffer for 1h at room temperature. Enhanced Chemi-Luminescence (ECL) was performed using an ECL kit (Thermo Scientific; Cat-32106) following detection and development on an X-ray film for optimised durations of exposure in a dark room. The films were then scanned and analysed by densitometry using ImageJ software.
Immunocytochemical staining. SH-SY5Y cells were fixed in 4% PFA at 4°C for 20 min at room temperature. The cells were then washed with 10mM PBS and permeabilized for 30 min with 10mM PBS containing 0.01% Triton X-100. The cells were then blocked in 1% BSA made in 10mM PBS containing 0.01% Triton X-100 for 1 h at room temperature, and then washed in 10mM PBS. Cell were then immunostained with primary antibodies (see below) diluted in 1% BSA-PBS containing 0.01% Triton X-100 for 12 h at 4°C, washed with 10mM PBS and then probed with secondary antibodies diluted 1% BSA-PBS containing 0.01% Triton X-100 for 1 h at room temperature. Nuclei were counter stained using DAPI at a concentration of 0.1µg/ml in 10mM PBS for one min. Following washes with 10mM PBS, imaging was carried out with an Olympus IX71 inverted microscope fitted with an Olympus DP70 camera and the resultant images were analysed using ImageJ software.

Antibodies. The following antibodies were used for Western blotting and immunocytochemical staining. Anti-GAPDH (SCBT; SC-47724, 1:1000(WB), 1:200(IF)); Anti-Smad1/5/9 (Abcam; ab66737, 1:1000(WB), 1:200(IF)); Anti-p-Smad1/5/9 (CST; 13820, 1:1000(WB), 1:200(IF)). HRP-conjugated anti-mouse (ThermoFisher; Cat-A27025) was used at 1:5000 and anti-rabbit ThermoFisher; Cat-31460) was used at 1:5000. Alexa Fluor-488 anti-rabbit and Alexa Fluor-594 anti-mouse conjugated antibodies were used at a concentration of 1:500 (Invitrogen).

qRT-PCR. Cells were removed from the tissue culture dish using a sterile cell scraper and centrifuged at 1500 rpm for 5 min at 4°C. Subsequently, the pellets were lysed in 500µl of Tris reagent and 250µl Chloroform, vortexed and centrifuged at 13,200 rpm for 10 min. The aqueous layer was separated into an Eppendorf tube and 500µl of isopropanol and vortexed briefly and centrifuged at 13,200 rpm for 15 min. The supernatant was discarded and the pellets were washed with 80% ethanol and re-pelleted by centrifugation at 13,200 rpm for 10 min, subsequently air dried for 30 min and dissolved in RNase free water. The RNA yield and purity were measured on a Nano drop with nuclease free water as blank. cDNA was synthesized using random hexamers. A High capacity cDNA reverse transcription kit (Life Technologies; cat. no 4368814) was used as per the manufacturers recomendations. The synthesized c-DNA was used for real time PCR using the Jump start SYBR green kit (Sigma; cat no. S4438). The primers used were as follows Hes5 FW: 5’ CGCATCAACACGAGCATCGAG 3’ RV: 5’ GACGAAGGCTTGTGCTGCT 3’, Zeb2 FW: 5’ CGACACTCTTGGCGAGGTTT 3’ RV: 5’ TCACCACGCAAGTCTTTGTT 3’ and Gapdh FW: 5’ CCACTAGGCCGCTCCTTGTT 3’ RV: 5’ ACCAGAGTTAAAAAGCAGGCC 3’. RT-PCR was performed on a Real time PCR machine by (Life technologies; cat no. 4376600). The data was then analysed by δδ-Ct method; values for individual genes calculated against an endogenous control.

To profile mRNA expression in the developing mouse VM, the levels of Strap and Nme1 mRNAs were quantified by real-time PCR relative to a geometric mean of mRNAs for the house keeping enzymes glyceraldehyde phosphate dehydrogenase (Gapdh), succinate dehydrogenase (Sdha) and hypoxanthine phosphoribosyltransferase-1 (Hprt1). Total RNA was extracted from dissected VM using the RNeasy lipid mini extraction kit (Qiagen, UK) and 5 µl was reverse transcribed for 1 h at 45°C using the AffinityScript kit (Agilent, UK) in a 25 µl
reaction according to the manufacturer’s instructions. 2 µl of cDNA was amplified in a 20 µl reaction volume using Brilliant III ultrafast qPCR master mix reagents (Agilent). PCR products were detected using dual-labeled (FAM/BHQ1) hybridization probes specific to each of the cDNAs (MWG/Eurofins, Germany). The PCR primers were: \(5'\)-CGGGTGAGAAGACTTTA-3' and reverse: \(5'\)-CACAGTTTGCCACAATCCT-3'; \(Nme1\) forward: \(5'\)-TCTCCCTTCTATCACCTG-3' and reverse: \(5'\)-CACACATCCTCCACACAA-3'; \(Gapdh\) forward: \(5'\)-GAGAAACCTGCCAAGTATG-3' and reverse: \(5'\)-GGAGTTGCTGTGAAGTC-3'; \(Sdha\) forward: \(5'\)-TCTCCGACATCGCTGGCCTG-3' and reverse: \(5'\)-GCCACGATCAAATTCTC-3'; \(Hprt1\) forward: \(5'\)-TTAGCAACGGCTTCCAGCAAC-3' and reverse: \(5'\)-GACATCCTCCACACAA-3'; Dual-labeled probes were: \(5'\)-FAM-TGTCCCATCTTCAGAACCGCT-BHQ1-3'; \(5'\)-FAM-TGTCCTTCAGAACCGCT-BHQ1-3'; \(5'\)-FAM-TGTCCTTCAGAACCGCT-BHQ1-3'; \(5'\)-FAM-TGTCCTTCAGAACCGCT-BHQ1-3'; \(5'\)-FAM-TGTCCTTCAGAACCGCT-BHQ1-3'; \(5'\)-FAM-TGTCCTTCAGAACCGCT-BHQ1-3'; Forward and reverse primers were used at a concentration of 150 nM and dual-labeled probes were used at a concentration of 300 nM. PCR was performed using the Mx3000P platform (Agilent) using the following conditions: 45 cycles of 95°C for 10 s and 60°C for 35 s. Standard curves were generated for each cDNA for every real time PCR run, by using serial five-fold dilutions of reverse-transcribed mouse adult brain total RNA (Zyagen, USA). Relative mRNA levels were quantified in four separate sets of dissected tissues for each age. Primer and probe sequences were designed using Beacon Designer software (Premier Biosoft, USA).

**Gene Expression Analysis of the Human SN and mouse SN.** Human SN gene expression data from healthy controls (GSE:60863) (Kang et al., 2011), and from PD and control subjects (GSE:49036) (Dijkstra et al., 2015), were analysed using the R2: Genomics Analysis and Visualization Platform (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). Pearson correlation analysis with a Bonferroni multiple testing correction was used to identify those genes with a significant correlation with \(STRAP\) and \(NME1\) expression, and to examine \(STRAP\)–\(NME1\) co-expression. All gene expression data were log2 expression values. Gene ontology (GO) enrichment analysis was performed at [www.geneontology.org](http://www.geneontology.org).

**Proteomics using label-free LC-MS/MS.** SHSY5Y cells were treated with 100 ng/ml GDF5 for 240 min and lysed in RIPA buffer supplemented with 1 mM sodium orthovanadate, 1mM sodium fluoride and complete protease inhibitor cocktail (Roche Molecular Biochemicals) for 30 min on ice. Lysates were centrifuged at 13,200 rpm for 20 min. Supernatants were resolved on an SDS-Page gel and the gel was cut and shipped to Fingerprint Proteomics (University of Dundee, UK). Proteins were extracted from the gel, followed by trypsin digestion and passage through an Ultima 3000 nano-LC machine for analysis with a flow duration of 2 h. The raw data files were then analysed using MaxQuant version 1.6.0.16 carbamidomethylation as a fixed modification, all standard contaminants were filtered, 1% FDR was used for peptide identification and LFQ intensities were procured, analysis was performed with match between runs. From the data procured from MaxQuant, the average LFQ intensities and the fold change ratios were calculated. A two tailed Paired Student’s t-test was performed to identify
significantly upregulated proteins. -Log 10 of P-values and Log2 of fold change were calculated and volcano plots were generated using the R-script EnhancedVolcano version 1.4.0 (https://github.com/kevinblighe/EnhancedVolcano) (R version 3.5.3).

**Transfections.** SH-SY5Y cells were plated in 24-well plates and allowed to grow overnight. Transfections were performed using TransIT-X2® reagent following the manufacturer's guidelines. For transfections with DsirNA, 25nM of siRNA of the following double-stranded siRNAs: Scrambled (siSCR) (FW: 5’-CGUUAAUCGCUAUAUACGCUAT-3’; RV-5’-AGCUCGUGUAUCUACCAGUCAG-3’), siNME1 (FW: 5’- GAGGACUGGUAGAUUCACGAGCT-3’; RV-5’- AGCCUCGUGUAACUACCAGUCAG-3’) and siSTRAP (FW: 5’- AGGAUAAACUGUUACGCAUAUAUGA-3’; RV-5’- UCAUAUUGCUGACCUACGUUACCUGU-3’). A STRAP-expressing plasmid was purchased from Origene (RC209149) and the vector backbone was pCMV6 with a CMV promoter, followed by an N-terminal Myc-DDk tag on the STRAP protein. FLAG-NM23-H1 was a gift from Judy Lieberman (Addgene plasmid #25000; http://n2t.net/addgene:25000; RRID: Addgene_25000) and the NME1/NM23 construct had an N-terminal Flag tag followed by the NM23 coding sequence in a pCMV4 vector. In all cases, cells were co-transfected with an eGFP-expressing plasmid to identify transfected cells. Where indicated, cultures were treated with 100 ng/ml GDF5 daily for 72 h.

**Neurite length analysis.** Transfection and treatments were performed in duplicates as described above. Cells were imaged using an Olympus IX71 inverted microscope with the CellSense suit. Five images were captured from each well and neurite length was analysed using Image J. The averages of all measurements from each independent experiment were obtained and used to compare differences in the length of neurites between groups.

**Animal Husbandry.** Adult female Sprague-Dawley rats were procured from Envigo, UK, and maintained on a 12h:12h light:dark cycle with access to food and water *ad libitum*. Rats were housed in groups of four in standard housing cages containing environmental enrichment. All experiments were conducted fully in accordance with the European Directive 2010/63/EU and under an authorisation granted by the Health Products Regulatory Authority Ireland (AE19130/P057).

**Virus Preparation and Stereotactic Surgery.** AAV2/5-GDF5, AAV2/5-Null and AAV2/6-Null viral vectors were produced by Vector Biosystems Inc, Philadelphia, USA. In brief, AAV2 inverted terminal repeats coding for human GDF5 were packaged using AAV6 or AAV5 capsid proteins, to produce AAV2/6 and AAV2/5 viral vectors and the corresponding empty control vectors. Transgene expression was driven by synapsin-1 promoter and enhanced using woodchuck hepatitis virus post-transcriptional regulatory element (WPRE). Stereotactic surgery was conducted under general anaesthesia induced by the inhalation agent isoflurane. Each animal was placed in a stereotactic frame, an incision was made to the scalp and a small hole was drilled into the skull. AAV-Control animals were administered 2 μL AAV2/5-Null (1.0×10^{10} vg/μL) + AAV2/6-Null (5.3×10^{9} vg/μL). AAV-GDF5 animals received 2 μL AAV2/5-GDF5 (1.3×10^{10} vg/μL) + AAV2/6-Null (5.3×10^{9} vg/μL). All vector
combinations were given unilaterally into the SN at coordinates AP-5.3, ML ±2.0, DV-7.2 relative to bregma, at an infusion rate of 1µl/min with an additional 2 min for diffusion, before withdrawal and suturing. Post-surgery, animals received the analgesic Carprofen (5 mg/kg, s.c.) and 5% glucose solution (i.p.) and were allowed to recover fully on a heating-mat before being returned to their home cages.

**Tissue Processing.** Animals were sacrificed 20 weeks post-surgery by transcardial perfusion-fixation under terminal pentobarbital anaesthesia (50 mg/kg) for immunohistochemical analyses. Brains were post-fixed in 4% paraformaldehyde for 24 h and cryoprotected in 30% sucrose solution with 0.1% sodium azide. Sections (30 µm thickness) were cut on a freezing stage sledge microtome and were used for immunohistochemistry.

**Immunohistochemical staining.** Coronal sections through the SN were mounted onto gelatine-coated slides and washed for 10 min in tris-buffered saline (TBS) solution. Non-specific antibody binding was blocked for 1 h using 3% goat serum diluted in TBS containing 0.02% Triton-X100 (TXTBS). Sections were incubated overnight at room temperature with primary antibody diluted in TXTBS containing 1% goat serum. Primary antibodies used were: TH (Merck Millipore; 1:500) and NME1 (Cell Signaling Technologies; 1:100). Following 3 x 5-min TBS washes, sections were incubated for 2 h in Alexa Fluor® 594 goat-anti-mouse IgG (Invitrogen; 1:200, and Alexa Fluor® 488 goat-anti-rabbit IgG (Invitrogen; 1:200) secondary antibodies diluted in TXTBS containing 1% goat serum. Sections were washed for 3 x 5-min using TBS and cover-slipped using fluorescent mounting media (Dako Diagnostics). Images were taken using the Olympus FV1000 Confocal Laser Scanning Biological Microscope.

**Statistical methods.** Statistical analyses was performed using GraphPad Prism version 6 (©2018 GraphPad software, CA USA). Students’s t-test, or one-way or two-way ANOVA with post-hoc tests as indicated in the Figure legends, were used as appropriate to identify statistically significant differences. All experiments were repeated independently at least three times.